Resmed Deferred Long Term Liab from 2010 to 2024
RMD Stock | 38.19 0.13 0.34% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 77.1 M | Current Value 52.1 M | Quarterly Volatility 20.2 M |
Check Resmed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Resmed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 227 M, Total Revenue of 4.9 B or Gross Profit of 2.8 B, as well as many indicators such as . Resmed financial statements analysis is a perfect complement when working with Resmed Valuation or Volatility modules.
Resmed | Deferred Long Term Liab |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Resmed Stock Analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.